Welcome to our dedicated page for Kkr & news (Ticker: KKR), a resource for investors and traders seeking the latest updates and insights on Kkr & stock.
KKR & Co. Inc. reports developments across its global investment business, including alternative asset management, capital markets activity and insurance solutions. Company news commonly covers operating results, fund and strategy activity, portfolio investments, co-investment vehicles, debt financing, and capital-structure updates.
KKR sponsors investment funds in private equity, credit and real assets, works with strategic partners that manage hedge fund platforms, and operates insurance subsidiaries that offer retirement, life and reinsurance products through Global Atlantic Financial Group. Recent company updates also reflect activity in technology growth, sports, sustainable infrastructure and insurance-related platforms.
KKR (NYSE:KKR) has announced a significant minority investment in ghSMART, a leading global leadership advisory firm, through its Ascendant Fund. Founded in 1995 by Dr. Geoff Smart, ghSMART has completed nearly 30,000 leadership assessments and over 5,000 C-Suite advisory engagements with a remarkable 98% client satisfaction rate.
The transaction maintains ghSMART's majority ownership with its founder, partners, and employees, while current CEO Jeff McLean continues to lead the company. KKR will support ghSMART's growth initiatives, including expanding its client base, developing digital product offerings, and enhancing its employee ownership program for all 173 employees.
KKR (NYSE:KKR) has released its 2025 Mid-Year Global Macro Outlook titled "Make Your Own Luck," authored by Henry McVey, CIO of KKR's Balance Sheet and Head of Global Macro and Asset Allocation. The report maintains a positive market outlook despite early 2025 turbulence, citing favorable financial conditions, global easing cycles, and productivity gains as key drivers.
The outlook presents several notable predictions, including WTI oil prices declining to $60 per barrel in H2 2025-2026, sustained low unemployment rates, and European markets outperforming expectations. The report emphasizes opportunities in Private Equity and Infrastructure investments, while advocating for assets with collateral-based cash flows and inflation-adjustment capabilities.
The analysis suggests focusing on control positions in Private Equity, senior Credit positions, and Real Assets with inflation-linked contracts as strategic investment approaches in the current market environment.KKR & Co. (NYSE: KKR), a leading global investment firm, has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025, before the NYSE market opening. The company will host a conference call at 9:00 a.m. ET on the same day to discuss the results.
Investors can access the call via phone at (877) 407-0312 (U.S.) or +1 (201) 389-0899 (international), or through the live webcast available on KKR's Investor Center website. A replay will be available on the company's website approximately one hour after the broadcast.
Perrigo (NYSE: PRGO) has announced an agreement to sell its Dermacosmetics branded business to KKR-managed Kairos Bidco AB for up to €327 million. The deal includes €300 million in upfront cash and up to €27 million in potential milestone payments tied to net sales performance over three years.
The transaction, expected to close in Q1 2026, is part of Perrigo's 'Three-S' strategic plan to Stabilize, Streamline, and Strengthen the organization. The divested brands include ACO, Biodermal, Emolium, and Iwostin, which generated approximately €125 million in net sales and about 5% of Perrigo's 2024 adjusted operating income.
Proceeds will be directed towards previously announced capital allocation priorities, including strengthening the company's balance sheet. The deal remains subject to regulatory approvals and works council consultation.
FS KKR Capital Corp. (NYSE: FSK) has scheduled its second quarter 2025 earnings release and conference call. The company will release Q2 2025 results after market close on Wednesday, August 6, 2025.
The earnings conference call will be held via webcast on Thursday, August 7, 2025, at 9:00 a.m. ET. Research analysts must pre-register at least 15 minutes before the call. An investor presentation will be available on FSK's website after market close on August 6, and a replay will be accessible in the Investor Relations section after the call.
KKR (NYSE:KKR) has announced the acquisition of ProTen Pty Limited, one of Australia's largest agricultural infrastructure businesses, from Aware Super. ProTen is a significant player in Australia's poultry supply chain, managing over 700 poultry sheds across more than 60 farms nationwide.
The acquisition represents KKR's strategic entry into the agricultural infrastructure space, with the investment being made through its Asia Pacific Infrastructure Investors II Fund. ProTen, established in 2001, has been under Aware Super's ownership since 2018, during which time it experienced significant growth including a four-fold expansion of its property portfolio.
The transaction, which is expected to close later in 2025 subject to regulatory approvals, adds to KKR's growing infrastructure portfolio in the Australia & New Zealand region, which includes investments in Zenith Energy, Queensland Airports Limited, Spark Infrastructure, and Ritchies Transport. KKR's Asia Pacific infrastructure platform currently manages approximately US$13 billion in assets.
KKR (NYSE:KKR) has announced its second residential investment in Stockholm through a forward funding agreement with Swedish developer Reliwe for a new multifamily development in Täby. The project consists of three residential assets totaling 325 units with approximately 15,300 square meters of lettable area, scheduled for completion between 2026 and 2028.
Located 14 kilometers from Stockholm's city center, the development offers excellent public transport connectivity and proximity to Täby Centrum shopping center. This investment follows KKR's February 2025 investment in Haninge, bringing their Stockholm residential portfolio to approximately 700 units under development. The project will be managed in partnership with local operator Cavendo.
KKR has committed over SEK 6 billion to real estate investments in the Nordics, focusing on residential and logistics assets. The investment is being made through KKR's European Real Estate strategy.
KKR (NYSE:KKR) has announced the launch of Ascend Asia Financial Services Group, a new financial advisory platform in Singapore. The platform's first strategic move includes the acquisition of finexis advisory and its affiliates through KKR-managed funds.
The platform will be led by CEO Tomas Urbanec, former CEO of Prudential Singapore, alongside a seasoned leadership team including Chief Risk & Compliance Officer Tan Siew Yen and General Counsel Leonard Ong. Patrick Teow, former CEO of AIA Singapore, will serve as Senior Advisor.
Ascend Asia aims to empower member firms by providing strategic expertise, industry knowledge, and resources to enhance their capabilities. finexis, as the inaugural member, will continue to operate under its own brand with no changes to existing client relationships. The transaction, which has received in-principle approval from the Monetary Authority of Singapore, is expected to close in Q3 2025.
KKR (NYSE:KKR) has announced an agreement to sell its controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma) to Torrent Pharmaceuticals in a significant two-phase transaction valued at INR 25,689 crores (on fully diluted basis).
The transaction structure includes: 1) Acquisition of 46.39% equity stake through a Share Purchase Agreement at INR 11,917 crores (INR 1,600 per share), followed by a mandatory open offer for up to 26% additional shares at INR 1,639.18 per share. 2) Merger between Torrent and JB Pharma where shareholders will receive 51 Torrent shares for every 100 JB Pharma shares.
The strategic acquisition strengthens Torrent's presence in the Indian pharmaceutical market, particularly in chronic segments, while providing entry into new areas like ophthalmology and CDMO capabilities. The deal requires approvals from various regulatory bodies including SEBI, Stock Exchanges, CCI, and NCLT.